Here's what to know about Medicare's new GLP-1 weight-loss drug program
Summary
Starting July 1, some Medicare patients can access GLP-1 weight-loss drugs by paying a $50 monthly copay through a new temporary program called Medicare GLP-1 Bridge. The program will last 18 months and covers certain medications made by Eli Lilly and Novo Nordisk for patients meeting specific health criteria.Key Facts
- The Medicare GLP-1 Bridge program begins July 1 and runs through December 31, 2027.
- It helps Medicare patients pay for GLP-1 drugs prescribed just for weight loss, not other conditions.
- Patients will pay a $50 monthly copay, which does not count toward their deductible or annual out-of-pocket limit.
- Eligible patients must have a qualifying BMI level and related health conditions, verified by a doctor.
- The program covers Lilly’s Foundayo and Zepbound and Novo Nordisk’s Wegovy in pill and injection forms.
- Patients already receiving GLP-1 drugs for conditions like diabetes under Medicare Part D are not eligible.
- The program is temporary, and coverage after 2027 depends on government decisions or changes in the law.
- Patients cannot use coupons or discounts to reduce the $50 copay in this program.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.